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Antidepressant medications are the ﬁrst-line treatment for people meeting current diag-
nostic criteria for major depressive disorder. Most antidepressants are designed to perturb
the mechanisms that regulate the neurotransmitter serotonin – an evolutionarily ancient
biochemical found in plants, animals, and fungi.Many adaptive processes evolved to be reg-
ulated by serotonin, including emotion, development, neuronal growth and death, platelet
activation and the clotting process, attention, electrolyte balance, and reproduction. It is a
principle of evolutionary medicine that the disruption of evolved adaptations will degrade
biological functioning. Because serotonin regulates many adaptive processes, antidepres-
sants could have many adverse health effects. For instance, while antidepressants are
modestly effective in reducing depressive symptoms, they increase the brain’s suscepti-
bility to future episodes after they have been discontinued. Contrary to a widely held belief
in psychiatry, studies that purport to show that antidepressants promote neurogenesis are
ﬂawed because they all use a method that cannot, by itself, distinguish between neuro-
genesis and neuronal death. In fact, antidepressants cause neuronal damage and mature
neurons to revert to an immature state, both of which may explain why antidepressants
also cause neurons to undergo apoptosis (programmed death). Antidepressants can also
cause developmental problems, they have adverse effects on sexual and romantic life,
and they increase the risk of hyponatremia (low sodium in the blood plasma), bleeding,
stroke, and death in the elderly. Our review supports the conclusion that antidepressants
generally do more harm than good by disrupting a number of adaptive processes regulated
by serotonin. However, there may be speciﬁc conditions for which their use is warranted
(e.g., cancer, recovery from stroke). We conclude that altered informed consent practices
and greater caution in the prescription of antidepressants are warranted.
Keywords: antidepressant medications, depression, mortality, placebo, rebound, risks, safety, side effects
INTRODUCTION
Serotonin (5-hydroxytryptamine or 5-HT) is an ancient chem-
ical, evolving at least one billion years ago, and it is present in
fungi, plants, and animals (Azmitia, 2007). It belongs to a class
of biochemicals called monoamines, which also includes norep-
inephrine (NE), and dopamine (DA). Many adaptive processes
evolved to be regulated by serotonin, including cell differentia-
tion, temperature, blood clotting, digestion and gut movement,
insulin, electrolyte balance, astrocytic activity, neuronal apopto-
sis, cerebral blood ﬂow, attention, aggression, mood, reproductive
function, and mating behavior (Johnson and Thunhorst, 1997;
Azmitia, 2001, 2007, 2010; Jimenez-Trejo et al., 2007; Fonseca et al.,
2009; Paulmann et al., 2009).
Abbreviations: MAOIs, monoamine oxidase inhibitors; MDD, major depressive
disorder; NSAIDs, non-steroidal anti-inﬂammatory drugs; SNRIs, serotonin norep-
inephrine reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs,
tricyclic antidepressants.
Drugs affecting the serotonergic system are among the most
widely prescribed psychiatric medications. Depression is the most
common psychiatric condition for which people seek help (Pin-
cus et al., 1999), and the symptoms are regulated, at least partly,
by serotonin and norepinephrine (Heisler et al., 1998; Mayorga
et al., 2001; Santarelli et al., 2003; Cryan et al., 2004; Amat et al.,
2005, 2006). About 6.6% of adults, or about 13 million of the
adult US population, are estimated to have depressive episodes
that meet current criteria for major depressive disorder (MDD)
within a year’s time (Kessler et al., 2007). Antidepressant medica-
tion is the most commonly prescribed treatment for depression
(Olfson et al., 2002), and most of these drugs target serotonin and
norepinephrine, although dopamine is affected to some degree as
well (Stahl, 2008). Commonly prescribed classes of antidepres-
sants are listed in Table 1. Antidepressants may also be prescribed
to people with subclinical depression and many other conditions,
including dysthymia, bipolar depression, schizoaffective disor-
der, post psychotic depression, generalized anxiety disorder, panic
disorder (with or without agoraphobia), social phobia, substance
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Table 1 | Classes of antidepressant drugs along with their chemical
and trade names (in parentheses).
Class Antidepressants
Selective serotonin
reuptake inhibitors (SSRIs)
Citalopram (Celexa), escitalopram (Lexapro),
ﬂuoxetine (Prozac), ﬂuvoxamine (Luvox),
paroxetine (Paxil), sertraline (Zoloft)
Serotonin norepinephrine
reuptake inhibitors (SNRIs)
Desvenlafaxine (Pristiq), duloxetine
(Cymbalta), milnacipran (Ixel), venlafaxine
(Effexor)
Norepinephrine dopamine
reuptake inhibitors (NDRIs)
Bupropion (Wellbutrin)
Tricyclic antidepressants
(TCAs)
Amitriptyline (Elavil), clomipramine
(Anafranil), desipramine (Norpramin),
imipramine (Tofranil), nortriptyline (Aventyl)
Tetracyclic antidepressants
(TetCAs)
Mianserin (Norval), mirtazapine (Remeron)
Monoamine oxidase
inhibitors (MAOIs)
Phenelzine (Nardil), selegiline (L-deprenyl,
Emsam)
abuse disorders, anorexia, bulimia, obsessive compulsive disorder,
post-traumatic stress disorder, and chronic pain syndromes. Thus,
millions of people are prescribed antidepressants and affected by
them each year.
The principle of primum non nocere requires physicians to do
no harm. However, there is increasing concern that current diag-
nostic criteria and treatment practices may do more harm than
good (Hagen, 2003; Horwitz and Wakeﬁeld, 2007; Kirsch et al.,
2008;Andrews and Thomson Jr., 2009; Fournier et al., 2010;Wake-
ﬁeld et al., 2010; Andrews et al., 2011; Fava and Ofﬁdani, 2011),
and these concerns are increasingly expressed in prominent pub-
lic outlets (Lehrer, 2010; Angell, 2011). Moreover, many of the
concerns have been driven by evolutionary conceptions about the
nature of disorder (Wakeﬁeld, 1992, 1999; Watson and Andrews,
2002; Hagen, 2003; Horwitz and Wakeﬁeld, 2007; Andrews and
Thomson Jr., 2009; Andrews et al., 2011).
It is a principle of evolutionary medicine that the disruption of
adaptive processes will degrade biological functioning (Nesse and
Williams,1994). For instance, a growingbodyof evidence indicates
that fever is an evolutionarily ancient adaptation for coordinat-
ing immune responses to infection (Kluger et al., 1997; Hasday
et al., 2000; Blatteis, 2003; Appenheimer et al., 2005). Studies in
humans have shown that the disruption of fever with antipyretic
(fever-reducing)medicationhas a number of adverse effects on the
immune response. In controlled experiments, antipyretic med-
ication lengthens the time it takes the body to clear non-fatal
infections such as rhinovirus (common cold) and Varicella zoster
(chickenpox; Stanley et al., 1975; Doran et al., 1989; Graham et al.,
1990). Acetaminophen also increased the duration of illness in
Plasmodium falciparum (malaria) infections in an experimental
paradigm (Brandts et al., 1997). In patients with more serious
infections, such as bacterial sepsis, correlational studies commonly
ﬁnd fever is associated with increased survival (Bryant et al., 1971;
Weinstein et al., 1978, 1983; Mackowiak et al., 1980; Swenson et al.,
2007; Rantala et al., 2009). There has been little experimental
research on the mortality effects of antipyretic therapy in humans
with serious infections. Inone experiment, ibuprofendidnot affect
mortality among patients with bacterial sepsis, butmedicationwas
not initiated until the infections had caused organ dysfunction
(Bernard et al., 1997). In a preliminary analysis of another experi-
ment where acetaminophen was administered to trauma patients
close to the onset of fever, seven out of 44 (16%) who received
medication died while only one out of 38 (3%) died in the group
receiving no medication (Schulman et al., 2005). The difference
was not quite statistically signiﬁcant (p = 0.06), but the study was
halted early. The university’s ethics review board had originally
granted a waiver of informed consent based on the assumption
that there was minimal risk involved, and the preliminary results
strongly suggested that this assumption was erroneous.
Given the broad distribution of serotonin inside and outside of
the brain (Berger et al., 2009), and the broad effects of serotonin
on adaptive processes, antidepressants could have many adverse
health effects. Despite considerable research, there has been little
emphasis on the broad serotonergic effects of antidepressants on
health in debates about antidepressant use.
In this article, we consider: (1) the broad effects of antidepres-
sants on putative pathological processes thought to be involved in
depression; (2) the effects of antidepressants on normal, adaptive
processes in the body as a whole; and (3) the issue of whether
antidepressants do more harm than good. Ultimately, we come
down on the side that the beneﬁts of antidepressants are gener-
ally outweighed by their costs (see Table 2), though there may be
speciﬁc populations where their use is warranted. Notably, our
argument does not depend on the efﬁcacy of antidepressants rela-
tive to other possible treatments for depression. Rather, it depends
on whether it is better for practitioners to refrain from prescribing
rather than to start a patient on antidepressants. For this reason,
we do not discuss non-pharmacological alternatives, although this
is an active area of research. Of course, we do not advocate that
practitioners not provide treatment; however, if results of a cost–
beneﬁt analysis suggest that providing no medication is a superior
choice compared to that of prescribing antidepressants in most
situations, then practitioners might be more inclined to employ
other treatments with a lower side effect proﬁle.
SEROTONIN AND HOMEOSTASIS
In animals, only about 5% of the body’s serotonin resides in the
brain. Most of the body’s serotonin is housed in the gut, with
90% of that stored in enterochromafﬁn cells (where most of it
is synthesized) and the remaining 10% is synthesized by and
stored in myenteric interneurons (Gershon, 2004). Enterochro-
mafﬁn cells also release serotonin into the blood stream, where
most of it is taken up by platelets. Serotonin does not pass the
adult blood–brain barrier, so central and peripheral sources do
not communicate with each other (Hranilovic et al., 2011).
Serotonin is normally under homeostatic control in the brain,
the gut, and blood plasma (Hyman and Nestler, 1996; Gershon,
2004; Lesurtel et al., 2008; Keszthelyi et al., 2009; Matondo et al.,
2009; Best et al., 2010; Mercado and Kilic, 2010). Homeostasis
involves the regulation of an important substance or physiological
parameter within a narrow range around an equilibrium. Home-
ostatic mechanisms are classic examples of evolved adaptations
because they maintain important physiological parameters at
Frontiers in Psychology | Evolutionary Psychology April 2012 | Volume 3 | Article 117 | 2
Andrews et al. Primum non nocere
Table 2 | Summary of costly (C) and beneficial (B) effects of antidepressant medications, with some estimate of their effect size or frequency.
Effect C/B Estimated effect size/frequency Reference
MOOD
Reduce depressive symptoms ? 1.8 HDRS points (not clinically signiﬁcant) Kirsch et al. (2008)
Relapse risk after discontinuation – 21.4% (unmedicated) See text
C 43.3% (SSRI) See text
C 47.7% (SNRI) See text
C 55.2% (TCA) See text
C 61.8% (ﬂuoxetine) See text
C 75.1% (MAOI) See text
NEUROCOGNITIVE EFFECTS
Neuronal death C ? See text
Anti-cancer effects B ? See text
Neuronal dematuration C ? Kobayashi et al. (2010)
Motor recovery after stroke B 9.7 Points improvement in Fugl-Meyer motor scale score Chollet et al. (2011)
Neuronal structural damage C Detectable within 4 days of a clinically relevant dose Kalia et al. (2000)
Mild cognitive impairment C 70% increased risk Goveas et al. (2011)
Driving accidents C SSRIs: 16% increased risk Gibson et al. (2009)
– TCAs: no signiﬁcant effect Gibson et al. (2009)
GASTROINTESTINAL EFFECTS
Diarrhea C 16.7% Zimmerman et al. (2010)
Constipation C 22.4% Zimmerman et al. (2010)
Upset stomach C 22.9% Zimmerman et al. (2010)
Nausea C 17.5% Zimmerman et al. (2010)
Abdominal pain C 13.8% Zimmerman et al. (2010)
VASCULAR EVENTS
Gastrointestinal bleeding C 1.7 Adjusted odds ratio for SSRI alone SeeTable 4
Cardiac events ? SSRIs: mixed results See text
Stroke C TCAs: increased risk See text
Elderly women C ≈1.4 Events/1000 person-years Smoller et al. (2009)
Elderly of both sexes (1 year risk, 65+ years old) – 2.23% (no antidepressant use) Coupland et al. (2011)
– 2.26% (TCAs) Coupland et al. (2011)
C 2.61% (SSRIs) Coupland et al. (2011)
C 3.04% (other antidepressants) Coupland et al. (2011)
REPRODUCTIVE FUNCTIONING
Sexual dysfunction C 25.8–80.3% Serretti and Chiesa (2009)
DEVELOPMENT
Congenital malformities C 1.89 Adjusted odds ratio (paroxetine) Cole et al. (2007)
ELECTROLYTE BALANCE
Hyponatremia C 0.5–32.0% frequency Moret et al. (2009)
SUICIDAL BEHAVIOR
Elderly of both sexes (1 year risk, 65+ years old) – 0.25% (no antidepressant use) Coupland et al. (2011)
C 0.43% (TCAs) Coupland et al. (2011)
C 0.55% (SSRIs) Coupland et al. (2011)
C 1.30% (other antidepressants) Coupland et al. (2011)
OVERALL MORTALITY
Elderly men (not depressed) C 1.22 Adjusted hazard ratio Almeida et al. (2010)
Elderly men (depressed) C 2.97 Adjusted hazard ratio Almeida et al. (2010)
Elderly women C ≈5/1000 Person-years Smoller et al. (2009)
Elderly of both sexes (1 year risk, 65+ years old) C 10.8/1000 Person-years (TCAs) Coupland et al. (2011)
C 35.7/1000 Person-years (SSRIs) Coupland et al. (2011)
C 43.9/1000 Person-years (other antidepressants) Coupland et al. (2011)
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levels needed for proper biological functioning (Hochochka and
Somero, 2002;Woods, 2009), and because they often have complex
machinery that could only have evolved by natural selection
(Andrews et al., 2011). Minimally, homeostatic mechanisms have
a sensor for determining how far the parameter deviates from the
equilibrium and feedback mechanisms for bringing the parameter
back to equilibrium (Woods, 2009). For instance, the homeostatic
control of core body temperature involves neuronal sensors in
the preoptic anterior hypothalamus that connect with various
efferent pathways to exert feedback and keep temperature at
equilibrium (Romanovsky, 2007). Additionally, many homeosta-
tic mechanisms can raise or lower the equilibrium in response to
environmental contingencies. Thus, the body often responds to
an infection by raising the core body temperature equilibrium –
otherwise known as fever (Romanovsky et al., 2005). Feedback
mechanisms then maintain core body temperature around this
elevated equilibrium.
We now discuss, in turn, how serotonin is homeostatically
regulated in the brain, gut, and blood plasma.
SEROTONIN IN THE BRAIN
In the brain, serotonergic neurons originate in the raphe nuclei
and project widely to various regions. The dorsal raphe nucleus is
the primary source of neurons projecting to forebrain areas. After
serotonin is released into the synapse, it is eventually taken back
into the presynaptic neuron by serotonin transporter molecules
where it is broken down by the enzyme monoamine oxidase A.
Synaptic levels of serotonin are homeostatically regulated, in
part, by 5-HT1A autoreceptors located on the somatodendritic
regions of serotonergic neurons that control neuronal ﬁring and
5-HT1B autoreceptors located in terminal regions that control the
synthesis of serotonin (Best et al., 2010). Thus,when synaptic levels
of serotonin are perturbed upwards from their equilibrium level,
autoreceptor activity causes a decrease in the ﬁring of serotoner-
gic neurons and a reduction in synthesis, both of which tend to
keep synaptic levels relatively stable (Best et al., 2010). Conversely,
when synaptic levels are perturbed downwards from equilib-
rium, ﬁring and synthesis increase to maintain equilibrium levels
(Best et al., 2010).
SEROTONIN IN THE GUT
Most of the serotonin in the body is produced by enterochro-
mafﬁn cells that line the digestive tract from the stomach to the
colon. Enterochromafﬁn cells turn over quickly because they form
part of the epithelial layer, so neurons cannot form tight junc-
tions with them. Consequently, enterochromafﬁn cells produce
large amounts of serotonin to compensate for the large interven-
ing distance from neurons (Gershon, 2004). However, too much
extracellular serotonin in the intestinal lining is harmful and can
cause irritable bowel syndrome, characterized by symptoms of
pain, diarrhea, constipation, indigestion, bloating, and headache
(Gershon, 2004). There are no extracellular enzymes for cataboliz-
ing serotonin, and mucosal epithelial cells play an important role
in maintaining homeostasis by clearing extracellular serotonin via
the same transporter that is expressed in the brain (Gershon and
Tack, 2007). These cells then catabolize serotonin by monoamine
oxidase or other pathways (Gershon, 2004).
SEROTONIN IN BLOOD PLASMA
The overﬂow of serotonin produced by enterochromafﬁn cells
is also released into the bloodstream (Gershon and Tack, 2007).
Blood plasma levels of serotonin are regulated by platelet cells via
the action of the serotonin transporter, which is expressed on the
platelet cell membrane (Linder et al., 2007; Mercado and Kilic,
2010).
Transporter molecules are stored in vesicles in the platelet cyto-
plasm and trafﬁcking between the surface and cytoplasmic stores
takes place as a function of plasma levels of serotonin (Mercado
and Kilic, 2010). When plasma levels of serotonin are low, a rel-
atively small increase in serotonin triggers a process by which
the surface expression of the transporter is increased, promoting
the accumulation in platelets and maintaining low plasma levels.
Platelets store serotonin in large granules that are crucial to the
clotting process (Heger and Collins, 2004), so this homeostatic
mechanism for regulating plasma serotonin levels is important for
ensuring that clotting mechanisms are primed for the onset of any
injuries.
Various cells in the skin (melanocytes, mast cells, Merkel cells)
can synthesize and store serotonin (Nordlind et al., 2008). When
an injury that punctures the skin takes place, free serotonin levels
rapidly increase in the area around the wound (Hernandez-Cueto
et al., 2000). A large localized increase in plasma serotonin lev-
els can reverse the surface expression of transporter in platelets
(Mercado and Kilic, 2010). Speciﬁcally, trafﬁcking reverses direc-
tion, reducing transporter expression on the surface, increasing
transporter accumulation in cytoplasmic vesicles, and reducing
the further uptake of serotonin into the platelet. Moreover, high
plasma levels of serotonin initiate a complex process by which the
cytoplasmic stores of serotonin trigger the release of procoagulants
from the platelet (Mercado and Kilic, 2010), which promotes the
clotting process at the site of injury.
THE EFFECTS OF ANTIDEPRESSANT MEDICATIONS ON BODY
SYSTEMS
According to themost prominent view inmedicine and psychiatry,
disorders stem from a breakdown or a decline in biological func-
tioning [American Psychiatric Association (APA), 2000b]. Since
natural selection is the only natural force capable of generat-
ing biological functions, and traits with biological functions are
called adaptations, disorders can be understood as involving a
breakdown or a decline in the functioning of evolved adapta-
tions (Wakeﬁeld, 1992, 1999). In principle, then, interventions that
degrade or disrupt the functioning of homeostatic mechanisms
can cause disorder.
Antidepressants are most commonly taken in pill form, though
there are some that can be taken through a transdermal patch. In
either case, they enter the bloodstream, pass through the blood–
brain barrier, and affect neuronal functioning. Antidepressants
perturb monoamine levels through a variety of mechanisms, the
most common of which is by binding to monoamine transporters.
In the normally functioning rodent brain, transporter blockade
prevents the reuptake of monoamines into the presynaptic neuron,
which causes extracellular monoamines to increase from equi-
librium levels in forebrain regions within minutes to hours of
administration (seeFigure 1; Rutter andAuerbach,1993;Bymaster
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FIGURE 1 |The effects of antidepressant medications on extracellular
levels of serotonin, the synthesis of serotonin, and overall forebrain
levels of serotonin, as a function of time.
et al., 2002; Felton et al., 2003).With prolonged antidepressant use,
however, the brain’s homeostatic mechanisms buffer this effect by
making a number of compensatory changes (Best et al., 2010),
including an inhibition of synthesis that causes the entire pool
of serotonin in the forebrain (intracellular plus extracellular) to
decline (Honig et al., 2009). Consequently, extracellular levels in
the forebrain return to equilibrium levels with prolonged treat-
ment (Popa et al., 2010). There are other changes that take place
with chronic antidepressant use to maintain homeostasis, includ-
ing alterations in the density and functioning of serotonin recep-
tors, transporters, and enzymes (Holt and Baker, 1996; Hyman
and Nestler, 1996; Adell et al., 2005; Kovacevic et al., 2010).
But antidepressants also spread widely throughout the body.
Because the serotonin transporter plays a crucial role in the home-
ostatic regulation of serotonin in the gut and plasma, antidepres-
sants can also inﬂuence serotonergic processes in the periphery.
There are a number of ways that antidepressants can disrupt
properly functioning homeostatic mechanisms in the brain and
periphery and cause disorder. The ﬁrst way is derived from the
fact that it takes several weeks for the decline in synthesis to bring
extracellular levels of serotonin in the brain back down to equilib-
rium levels. During this time, serotonin levels are higher than what
they should be. Antidepressants could potentially cause disorder
prior to the restoration of equilibrium.
Second, the long-term use of antidepressants can strain home-
ostatic regulatory mechanisms, because they must make a number
of accommodations to restore equilibrium, and this can degrade
the functioning of those mechanisms. For instance, it has been
suggested that depression could potentially be the result of decline
in the functioning of regulatory mechanisms caused by prolonged
stress (McEwen, 2000; Ganzel et al., 2010). The same principle
suggests that long-term antidepressant use could potentially cause
degradation in the functioning of the homeostatic mechanisms
controlling serotonin.
Third, antidepressants can trigger disorder when they are dis-
continued. Even though equilibrium is eventually restored with
prolonged antidepressant use, it only does so because the accom-
modations made by the brain oppose the action of antidepressants
(Andrews et al., 2011; Fava and Ofﬁdani, 2011). When antidepres-
sants are discontinued, the accommodationsmade by the brain are
unopposed, which should again cause serotonin levels to deviate
from equilibrium. Thus, the discontinuation of antidepressants
can cause disorder until the brain reverses the accommodations
made during treatment.
Finally, antidepressants can cause disorder by effectively dis-
abling a key part of the homeostatic mechanism. For instance,
the homeostatic regulation of serotonin in the gut and the blood
plasma rely primarily on the serotonin transporter (Gershon,2004;
Mercado and Kilic, 2010). By blocking the transporter, antidepres-
sants interfere with a key part of the homeostatic mechanism such
that it is not possible to return the system to the equilibrium.
As we discuss the negative effects of antidepressants on
serotonin-regulated processes throughout the body,we sometimes
do not know precisely which of these mechanisms is at work or
whether other unknown mechanisms are at work. But these mech-
anisms are proof of the principle that antidepressants can have
transient or long-lasting effects that disrupt the proper functioning
of homeostatic mechanisms.
DEPRESSED MOOD
Research in rodents in which the homeostatic mechanisms reg-
ulating serotonin and norepinephrine are temporarily or perma-
nently disabled has provided strong experimental evidence that
monoamines play a role in regulating the behavioral symptoms
of depression (Heisler et al., 1998; Mayorga et al., 2001; Santarelli
et al., 2003;Cryan et al.,2004;Amat et al.,2005,2006).However, the
precise relationship between serotonin and depressive symptoms
is a matter of debate (Sapolsky, 2004; Andrews and Thomson Jr.,
2009). The oldest neurochemical disorder hypothesis for depres-
sion posits that serotonin and other monoamines are depleted – at
least in people with severe episodes of depression – and antide-
pressants correct this imbalance. For the purposes of this paper,
we do not need to know the precise relationship. The fact that
depressive symptoms are under serotonergic control, and sero-
tonin is under homeostatic control, suggests that the brain could
push back against the mood lowering effects of antidepressants
during treatment (Andrews et al., 2011).
MODEST EFFICACY OF ANTIDEPRESSANTS DURING
TREATMENT
Antidepressants are widely thought to be effective in reducing
symptoms. However, recent research strongly suggests that they
are only modestly effective at best. For instance, studies showing
a positive effect of antidepressants over placebo have been selec-
tively published (Turner et al., 2008). Turner et al. (2008) applied
to the US Food and Drug Administration (FDA) under the Free-
dom of Information Act (FOIA) to get access to the published
and unpublished studies submitted by pharmaceutical companies
to get governmental approval for their drugs. They found that
94% of the published studies showed an advantage of antidepres-
sants over placebo. When the published and unpublished studies
were considered together, only 51% showed an advantage over
placebo.
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Kirsch et al. (2008) also applied to the FDA under the FOIA
to understand how much more effective antidepressants were at
reducing depressive symptoms compared to placebo. Changes in
depressive symptoms were measured with the 17-item Hamil-
ton Depression Rating Scale (HDRS; Hamilton, 1960), the most
common instrument for assessing the efﬁcacy of antidepressant
medications in clinical trials. Scores can range from 0 to 53, and
researchers interpret them in a variety of ways (Kearns et al., 1982;
Cohn and Wilcox, 1992; Angst et al., 1993). The American Psychi-
atric Association (APA) (2000a) speciﬁcally mentions the scheme
used by Kearns et al. (1982), and it is formally used by the National
Institute for Clinical Excellence (NICE) in Great Britain (National
Institute for Clinical Excellence, 2004) (see Table 3).
Two other things about the HDRS are noteworthy. First,
patients with a score of 13 or higher typically meet formal diag-
nostic criteria for an episode of MDD (Bagby et al., 2004). In
other words, many people who meet diagnostic criteria for MDD
only have mild/moderate symptoms according to NICE guide-
lines. Second, NICE guidelines require an antidepressant drug to
reduce symptoms by three HDRS points or more than placebo to
be considered clinically signiﬁcant (National Institute for Clinical
Excellence, 2004).
On average, Kirsch et al. (2008) found that patients on placebo
experienced a 7.8 point reduction in HDRS symptoms while those
on antidepressants experienced a 9.6 point reduction. This might
seem like both groups improved substantially, but with the excep-
tion of one study, patients in all studies were, on average, in the
“very severely” depressed range (mean HDRS≥ 23) at entry. In
other words, even with the improvement in symptoms caused
by both placebo and antidepressants, most patients would prob-
ably still have satisﬁed diagnostic criteria for MDD. Moreover,
on average, antidepressants reduced symptoms by only 1.8 HDRS
points more than placebo. While this was a statistically signif-
icant difference, this was not sufﬁcient to meet NICE clinical
signiﬁcance guidelines. The difference between antidepressant and
placebo did increase with initial HDRS scores, and it reached clin-
ical signiﬁcance with baseline scores of 28 or higher. However,
antidepressants did not reach clinical signiﬁcance at high HDRS
scores because they were increasing in efﬁcacy; rather, it was due
to a decline in the efﬁcacy of placebo.
Interpreted straightforwardly, the results suggest that antide-
pressants do not really have much clinical effect on depressive
symptoms, except perhaps in patients in the “very severe” range.
The ﬁnding that antidepressants have modest symptom reduc-
ing effects relative to placebo has been replicated in several other
studies (Khan et al., 2002, 2005, 2011; Fournier et al., 2010). The
British consider the difference betweenplacebo and antidepressant
Table 3 | Interpretation of HDRS score.
HDRS score Severity of symptoms
0–7 Normal
8–13 Mild depression
14–18 Moderate depression
19–22 Severe depression
≥23 Very severe depression
to be small enough to recommend that antidepressants not be used
except in cases of severe depression (Bonin, 2012). Recently, in an
interview on the news program 60 Minutes, a representative of the
USFDAstated that the symptomreducing effect of antidepressants
relative to placebo is “rather small” (Bonin, 2012).
Some have taken the evidence of the limited efﬁcacy of antide-
pressants as evidence that serotonin is not involved in regulating
depressive symptoms. However, limited efﬁcacy is also expected
under the hypothesis that the homeostatic mechanisms regulating
serotonin are still intact, because the brain is expected to push back
against the effects of antidepressants (Andrews et al., 2011).
EFFECTS OF PROLONGED ANTIDEPRESSANT TREATMENT
Even among those who respond to antidepressant treatment,
longer-term use is associated with a loss of symptom reducing
efﬁcacy – sometimes causing a full-blown relapse. This is also con-
sistent with the brain pushing back against the symptom reducing
effect of antidepressants. In an early review, studies showed that
9–57% of long-term antidepressant users met formal criteria for a
relapse or a recurrence (Byrne and Rothschild, 1998). More recent
studies have found similarly high rates of relapse among those
who initially remitted on the drug. In one study of ﬂuoxetine,
35.2% met relapse criteria after 6months of continuous treat-
ment, increasing to 45.9% after 12months (McGrath et al., 2006).
In another study, 68% of patients who initially met remission
criteria, andwere exposed only to continuous antidepressant treat-
ment, had a relapse over a 2 year period (Bockting et al., 2008). Of
course, these studies only report increases in symptoms that meet
formal criteria for a relapse. A more general loss of efﬁcacy with
prolonged antidepressant use must be substantially higher.
SEQUENCED TREATMENT ALTERNATIVES TO RELIEVE DEPRESSION
The results of the Sequenced Treatment Alternatives to Relieve
Depression (STAR∗D) study are worth detailed description. This
study has widely been reported as evidence that antidepressants
are effective in the long-term reduction of depressive symp-
toms, especially if an alternative antidepressant with a broader
monoaminergic proﬁle is administered after a narrower one fails
(Insel and Wang, 2009). The 3110 patients who met inclusion cri-
teria for STAR∗D were put through a maximum of four sequential
pharmacological treatments, where a new treatment was initiated
conditional on failing to respond to the prior one. The overall
remission rate for patients who completed all treatment steps was
reported to be 67% (Rush et al., 2006).
However, STAR∗D did not include a placebo control group,
so any positive responses are not simply attributable to antide-
pressants – they are attributable to both antidepressants and the
placebo effect. Since there was no placebo group, it is not possible
to estimate how effective antidepressants were. Moreover, focus-
ing on only those patients who completed all the treatment steps
obscures the fact that 93%of the 1518 patients whomet criteria for
remission in one of the four steps either relapsed during 12months
of treatment or dropped out of the study (Pigott et al., 2010). Even
with no placebo control group, this awkward fact also suggests that
antidepressants have limited long-term efﬁcacy at best. The 93%
relapse/dropout rate was not reported in the primary STAR∗D
publications. Rather, it was reported by outside researchers who
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re-analyzed the data (Pigott et al., 2010). These outside researchers
have also documented numerous instances of apparent bias in the
reporting of results by STAR∗D researchers (Pigott et al., 2010).
INCREASED RISK OF RELAPSE AFTER ANTIDEPRESSANT
DISCONTINUATION
When homeostatic mechanisms are perturbed from equilibrium,
they produce an opposing force that is proportional to the degree
of perturbation. For instance, when you compress a spring from
its equilibrium position, it produces an opposing force and the
strength of this force increases as you compress it further. More-
over, when you release your hand from the compressed spring, it
ﬁrst overshoots the equilibrium position before returning to equi-
librium, and the degree of overshoot is proportional to how much
you compressed it.
Antidepressants vary in how much they perturb forebrain
monoamine levels, which is analogous to saying that they com-
press the spring to varying degrees. If the homeostaticmechanisms
regulating monoamine levels are properly functioning in most
people diagnosed with MDD, then we should see an overshoot in
depressive symptoms when they are discontinued. Moreover, the
degree of overshoot should be proportional to the strength of the
antidepressant.
To test the overshoot prediction,we recently conducted a meta-
analysis of studies in which antidepressants are discontinued. Data
are lacking on how much antidepressants perturb monoamines
in the human brain because it requires invasive techniques, so
we examined how much they increase monoamines in a region
of the rodent prefrontal cortex implicated in controlling depres-
sive symptoms (Amat et al., 2005). Placebo has no effect on
monoamine levels in the rodent brain, but the strongest anti-
depressants can increase prefrontal monoamine levels by 400%
or more (Bymaster et al., 2002). After controlling for covariates,
we found strong positive relationships between the risk of relapse
after discontinuation and the degree to which the antidepressant
used in the study increases serotonin (Figure 2) and norepineph-
rine (Figure 3). In other words, the more antidepressants perturb
monoamine levels in the brain, the more the brain appears to
push back, which increases the risk of relapse when the drug is
discontinued. This positive relationship also strongly suggests that
patients who get better without the use of antidepressants (i.e.,
when serotonin and norepinephrine levels are not perturbed) will
have a lower risk of relapse.
Altogether, the results of our meta-analysis further support
the hypothesis that the homeostatic mechanisms regulating sero-
tonin and norepinephrine are pushing back against the effects of
antidepressants. The fact that this pushback occurs in patients
meeting current diagnostic criteria for MDD casts some doubt
on the hypothesis that serotonin levels are dysregulated in such
patients. This is because the sensor and negative feedback com-
ponents of the homeostatic mechanisms must be functioning to
produce pushback against the effects of antidepressants. However,
our results do not rule out some dysfunction in the component
that sets the equilibrium.
The results also are inconsistent with hypotheses that antide-
pressants interrupt stress responses and give the brain a chance
FIGURE 2 |The risk of relapse after antidepressant discontinuation (y -axis) versus the perturbational effect of antidepressants on serotonin in the
rodent medial prefrontal cortex (x -axis), after controlling for covariates. A score of 100 on the x -axis means the antidepressant has no effect on serotonin
levels.
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FIGURE 3 |The risk of relapse after antidepressant discontinuation (y -axis) versus the perturbational effect of antidepressants on norepinephrine in
the rodent medial prefrontal cortex (x -axis), after controlling for covariates. A score of 100 on the x -axis means the antidepressant has no effect on
norepinephrine levels.
to heal so that it can become more resilient to depression (Sapol-
sky, 2001; Kramer, 2005). Instead, antidepressant use appears to
increase susceptibility to depression.
To show how different antidepressants affect the risk of relapse,
for this paper we conducted a regression analysis on this dataset
including the major antidepressant classes and controlling for the
covariates we identiﬁed as being important in our prior work.
Fluoxetine is unique among the SSRIs in that it increases pre-
frontal norepinephrine levels through a mechanism other than
reuptake blockade (Bymaster et al., 2002), so we separated it
from the other SSRIs. The estimated 3-month risk of relapse for
patients who had remitted while on placebo was only 21.4%,while
the risk after antidepressant discontinuation generally increased
with the monoaminergic perturbational effect of the class: 43.3%
(SSRI), 47.7% (SNRI), 55.2% (TCA), 61.8% (ﬂuoxetine), and
75.1% (MAOI).
NEURONAL PROLIFERATION, DEATH, AND DIFFERENTIATION
Serotonin is involved in shaping the brain through a number of
developmental processes, including cell differentiation, neuronal
apoptosis (programmed neuronal death), neurogenesis (the birth
and growth of new neurons), and neuroplasticity (Azmitia, 2001).
Because of the complex role that serotonin plays in shaping the
brain, antidepressants could have complex effects on neuronal
functioning.
Many studies have been conducted purporting to show that
antidepressants promote neurogenesis (Hanson et al., 2011), and
some have argued that this could be a fundamental and beneﬁcial
part of the antidepressant response (Santarelli et al., 2003; Duman,
2004; Warner-Schmidt and Duman, 2006; Perera et al., 2011).
Many also consider neurogenesis to be useful because it could
promote healing of neuronal damage that is purportedly caused
by depression (Sapolsky, 2001).
At the same time, the assumption that neurogenesis is a ben-
eﬁcial effect of antidepressants should not be accepted uncrit-
ically. Neurogenesis is carefully regulated over the life span
because cognitive functioning does not bear a simple relation-
ship to the number of neurons in the brain. In fact, if anti-
depressants were really effective in promoting the proliferation
of new neurons, clinicians would have to weigh any possible
utility of antidepressants with the possibility that they could
trigger brain tumors (Jackson, 2009). However, there is growing
in vitro evidence that antidepressants reduce gliomas and neurob-
lastomas, and these effects are mediated by neuronal apoptosis
(Levkovitz et al., 2005; Cloonan and Williams, 2011). In fact, a
recent epidemiological study suggests that prolonged TCA use
in humans may protect against gliomas (Walker et al., 2011),
although antidepressants may increase the risk of other forms
of cancer (Cosgrove et al., 2011). Apoptotic effects are not lim-
ited to neoplastic tissue. Antidepressants have been found to
cause cell death in non-cancerous hippocampal neurons in vitro
(Post et al., 2000; Bartholoma et al., 2002) and in vivo (Saira-
nen et al., 2005). They have also been found to cause cell death
in sperm cells (Tanrikut et al., 2010). In short, there is good
evidence from several different lines that antidepressants trigger
apoptosis.
Frontiers in Psychology | Evolutionary Psychology April 2012 | Volume 3 | Article 117 | 8
Andrews et al. Primum non nocere
It would be extremely odd if antidepressants directly and con-
comitantly promoted both neurogenesis and neuronal apoptosis.
In fact, the evidence of antidepressant triggered neurogenesis is
equivocal (Jackson, 2009). At the heart of the matter is the fact
that all the studies testing for neurogenesis use a method called
5-bromo-2′-deoxyuridine (BrdU). Other methods may be used
as well, but BrdU is nearly always used. BrdU is an analog of
the nucleoside thymidine that is incorporated into DNA dur-
ing synthesis, and the incorporated compound can be detected
using immunohistochemistry. Thus, BrdU is a marker of DNA
synthesis, which might make it seem to be a good marker of cel-
lular proliferation, since DNA must be synthesized for a cell to
divide. However, the interpretation of the BrdU signal is com-
plicated by the fact that BrdU can be incorporated into DNA
during processes other than neurogenesis, including DNA repair,
abortive cell cycle reentry, and DNA duplication without cellular
division (Taupin, 2007). Of particular relevance is the fact that
DNA is often synthesized during processes that lead to apopto-
sis (Taupin, 2007). The interpretational problems with BrdU have
led one reviewer to state that BrdU is “one of the most misused
techniques in neuroscience” (Taupin, 2007, p. 198). Other com-
mentators have stated that “bromodeoxyuridine (BrdU) labeling
is often uncritically accepted as proof of neurogenesis when it may
well be attributable to a cell cycle-related cell death” (Herrup et al.,
2004, p. 9232).
More recently, researchers have used othermethods in conjunc-
tion with BrdU to attempt to ascertain the fate of neurons after
antidepressant use. Common methods involve assessing neurons
for Ki-67 and doublecortin (DCX), both of which are proteins
expressed by maturing neurons still going through the cell cycle,
andNeuN,which is thought to be amarker of mature neurons that
is expressed after doublecortin is downregulated. Positive signals
for Ki-67, DCX, or NeuN are frequently interpreted as provid-
ing stronger evidence that antidepressants have triggered neuronal
growth.
However, a recent study using more sophisticated methodology
found no evidence that the antidepressant ﬂuoxetine increased
neurogenesis (Kobayashi et al., 2010). But it did ﬁnd evidence that
ﬂuoxetine caused mature neurons to take on immature functional
characteristics, including an immature proﬁle of synaptic plasticity
and gene expression. Since Ki-67 and DCX are expressed in imma-
ture neurons, it is quite possible that dematured neurons increase
their expression of Ki-67 and DCX. Importantly, Kobayashi and
colleagues found that the dematuredneurons still expressedNeuN.
Altogether, it is not clearwhether any of themethods typically used
to assess neuronal growth and maturation are in fact responding
only to apoptosis and dematuration.
The dematuration of neurons could be caused by the reduc-
tion of serotonin synthesis that occurs when the brain pushes
back against the synaptic-enhancing effects of antidepressants (see
Figure 1;Honig et al., 2009).Constant serotonergic input is needed
to maintain the mature state of neurons (Azmitia, 2001). When
serotonin synthesis is inhibited by parachlorophenylalanine, the
cytoskeleton disassembles and synapses and dendrites are lost as
neuronal processes retract, all of which indicate a return to an
immature, undifferentiated state (Chen et al., 1994; Wilson et al.,
1998; Azmitia, 2001).
Neuronal dematuration, particularly the retraction of neuronal
processes, appears to play a role in triggering apoptosis (Azmitia,
2001), which could explain why antidepressants induce neuronal
death. But the functional reason for why “dematuration” triggers
apoptosis is not precisely clear. Apoptosis plays a role in remov-
ing damaged cells and maintaining homeostasis of differentiated
tissues by regulating the equilibrium between the cell death and
cell birth (Hengartner, 2000). To maintain tissue homeostasis,
inappropriately proliferating cells must be detected and killed.
Thus, the body must be able to differentiate between controlled
and uncontrolled proliferation to appropriately direct apoptotic
processes. Dematuration might be viewed as a signal that the neu-
ron is changing into a malignant proliferative state, making it a
target for apoptosis. Similarly, pharmacologically forcing mature
neurons to go through a cell cycle causes them todie through apop-
totic processes (Herrup et al., 2004), perhaps because the sudden
change in proliferative status marks them as possible neoplasms.
Anotherway antidepressants could target neurons for apoptosis
is by directly inﬂicting structural damage on them, since damaged
neurons are often the targets of apoptosis (Cotran et al., 1998;
Stergiou and Hengartner, 2004). We are only aware of one study
that has tested whether antidepressants cause structural damage
to neurons (Kalia et al., 2000). The study authors found that expo-
sure to clinically relevant doses of ﬂuoxetine (11.4mg/kg, oral)
or sertraline (28.6mg/kg, oral) for only 4 days caused shortened
axons, kinks, and swollen nerve terminals in the brains of oth-
erwise healthy rodents. Such morphological changes are often
taken as de facto evidence of neuronal damage (Kalia et al., 2000),
and similar morphological features are thought to play a role in
Parkinson’s disease (Cheng et al., 2010).
Even if they do not directly promote neurogenesis, antidepres-
sants could do so indirectly. When pharmacological interventions
trigger neuronal apoptosis, the brain attempts to homeostatically
compensate byupregulatingneurogenesis. For instance, the induc-
tion of neuronal apoptosis in the hippocampus by kainic acid
was subsequently followed by an upregulation in neurogenesis
in the dentate gyrus and CA3 (Dong et al., 2003). The evidence
of neurogenesis was not signiﬁcant 18 days after the administra-
tion of kainic acid, but it was signiﬁcant after 33 days. One study
has shown that ﬂuoxetine increased neuronal progenitor cells,
but this was only 30 days after ﬂuoxetine treatment had stopped
(Encinas et al., 2006). It seems possible that antidepressants only
induce neurogenesis indirectly as a result of the brain attempting
to compensate for their apoptotic effects.
In general, neuronal dematuration and damage are likely to
interfere with proper brain functioning (Jackson, 2008, 2009). The
Parkinsonian-like morphological characteristics caused by anti-
depressants could explain why antidepressants can induce tardive
dyskinesia (involuntary, repetitive body movements; El-Mallakh
et al., 2011). In rodents, repeated administrationof antidepressants
has been found to impair performance on a variety of learn-
ing tasks, including passive avoidance, elevated plus maze, and
three-panel runway tasks (Ulak et al., 2006; Mutlu et al., 2011).
In humans, a recent large epidemiological study has found that
prolonged antidepressant use was associated with a 70% increase
in the risk of mild cognitive impairment in elderly women and an
increased risk of probable dementia (Goveas et al., 2011).
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ATTENTION
A common symptom of depression is difﬁculty concentrating.
This is due to the fact that depressed people often have persis-
tent thoughts related to their episode called ruminations that are
resistant to distraction and difﬁcult to suppress. These rumina-
tions interfere with the ability to concentrate on other things. In
other words, depression clearly affects the allocation of limited
attentional resources – particularly working memory (Andrews
and Thomson Jr., 2009). These attentional resources are at least
partly controlled by serotonin (Carter et al., 2005; Andrews and
Thomson Jr., 2009). Consequently, antidepressants could disrupt
attentional processes.
One study has shown that the antidepressant sertraline
decreases rumination in patients with dysthymia (Kelly et al.,
2007). The reduction of rumination is widely thought to be ben-
eﬁcial, however the scientiﬁc literature suggests otherwise. Inter-
ventions that disrupt rumination (e.g., distraction, thought sup-
pression) do tend to reduce symptoms in the short-term (Morrow
andNolen-Hoeksema, 1990;Nolen-Hoeksema andMorrow,1993;
Vickers and Vogeltanz-Holm, 2003; Park et al., 2004; Andrews
et al., 2007), but they tend to increase symptoms in the long-
term (Schmaling et al., 2002; Wenzlaff and Luxton, 2003; Hayes
et al., 2005), suggesting that the short-term effects are palliative
and do not address cause (Andrews and Thomson Jr., 2009). On
the other hand, interventions that encourage rumination (e.g.,
writing about one’s strongest thoughts and feelings related to the
episode) have been found to increase insight and shorten the dura-
tion of episodes (Hayes et al., 2005, 2007; Gortner et al., 2006;
Graf et al., 2008), suggesting that these interventions address cause
(Andrews and Thomson Jr., 2009). In other words, the disruption
of rumination may not be productive.
In any event, other research shows that antidepressants
have negative effects on attention. When administered to non-
depressed volunteers for several weeks, they tend to impair cogni-
tion (Hindmarch, 2009), particularly on tasks that require highly
focused working memory or vigilance (Schmitt et al., 2001, 2002;
Riedel et al., 2005).
Of particular interest are experiments showing that antidepres-
sants interfere with driving performance – a task that requires
sustained vigilance (Ramaekers et al., 1995; O’Hanlon et al., 1998;
Wingen et al., 2005). Recently, these researchers have extended
their studies to examine the effects of antidepressants and other
prescription drugs on real world driving accidents using a pri-
mary care database in the United Kingdom (Gibson et al., 2009).
Using the year prior to drug exposure as a baseline [incident rate
ratio (IRR)= 1], people who took SSRIs were at a greater risk of
a driving accident in the 4-week period before ﬁrst being pre-
scribed the drug (IRR= 1.7, 95% CI= 1.47–1.99). This suggests
that depression, anxiety, or other conditions that lead to anti-
depressant use are risk factors for accidents. In the ﬁrst 4-week
period of SSRI use, however, the risk of driving accidents returned
to baseline (IRR= 0.92, 95% CI= 0.75–1.12). Taken in isolation,
this would seem to suggest antidepressants protect against driving
accidents. But SSRIs only reduce symptoms after several weeks
of continuous use, and this was not a placebo-controlled study,
so it is possible that the reduced risk was attributable to other
effects of seeking help rather than the SSRI. Indeed, there was a
similar reduction in driving accident risk in the 4-week period
of ﬁrst use of other drugs that interfere with attention (benzodi-
azepines, non-benzodiazepine hypnotics, beta-blockers, opioids,
and antihistamines). After 4 weeks of use, however, the risk of
driving accidents increased and remained increased for the dura-
tion of SSRI treatment (IRR= 1.16, 95% CI= 1.06–1.28). Once
SSRI treatment was discontinued, the risk of accidents returned
to baseline (IRR= 1.03, 95% CI= 0.92–1.16). Similarly, benzodi-
azepines, non-benzodiazepine hypnotics, opioids, and antihista-
mines showed an increased risk of accidents with prolonged use
that returned to baseline upon discontinuation. Overall, the pat-
tern suggests that SSRIs – as well as benzodiazepines, hypnotics,
opioids, and antihistamines – increase the risk of driving accidents.
Antidepressant use is associated with an increased risk of falling
and bone fractures in the elderly (Cumming, 1998). This may also
be attributable to the effects of antidepressants on attention, since
avoiding falls requires vigilance in the elderly (Holtzer et al., 2007).
However, the risk of bone fracture after a fall is probably increased
because SSRIs lower bone mineral density (Moret et al., 2009).
GASTROINTESTINAL FUNCTION
Antidepressants that block the serotonin transporter can cause
long-term increases in serotonin in the gut because transporter
uptake is the primary mechanism for clearing serotonin. There are
backup transporters that can take up serotonin in the gut, but they
are less efﬁcient and do not completely compensate for the loss of
function of the serotonin transporter (Gershon and Tack, 2007).
As discussed above, elevated levels of serotonin in the intestinal
lining are associated with irritable bowel syndrome, character-
ized by pain, diarrhea, constipation, indigestion, bloating, and
headache. Antidepressants that bind to the serotonin transporter
could cause similar symptoms. In fact, pain, diarrhea, constipa-
tion, indigestion, bloating, and headache are common side effects
of antidepressants, with frequencies ranging from 13.8 to 22.9%
in one recent study (Zimmerman et al., 2010).
PLATELET ACTIVATION AND THE CLOTTING PROCESS
Serotonin is involved in platelet activation, which is important
in the clotting process (Heger and Collins, 2004). Platelets take
in serotonin from the plasma via the serotonin transporter, and
the serotonin molecules aggregate in the form of dense granules.
When these granules are released, they activate processes that cause
pro-aggregating proteins to be released from the platelet (Heger
and Collins, 2004). Thus, the clotting process requires stores of
serotonin in platelets.
Platelet activation also plays a role in atherosclerosis and throm-
bosis (Gawaz et al., 2005; Weber, 2005). Research on depressed
patients has shown that plasma levels of serotonin are reduced,
platelet levels are elevated, and pro-aggregating processes are
enhanced, possibly increasing the risk of cardiovascular events
(Musselman et al., 2000; Bakkaloglu et al., 2008; Flock et al., 2010).
Antidepressants that bind to the serotonin transporter, such as
the SSRIs, can affect processes that depend on platelet activation.
SSRIs block the uptake of serotonin into the platelet, which causes
serum levels of serotonin to increase, platelet levels to decrease,
and the inhibition of pro-aggregating processes (Musselman et al.,
2000; Bakkaloglu et al., 2008; Flock et al., 2010).
Frontiers in Psychology | Evolutionary Psychology April 2012 | Volume 3 | Article 117 | 10
Andrews et al. Primum non nocere
ABNORMAL BLEEDING
Consistent with inhibition of the clotting process, there is growing
evidence that SSRIs increase the risk of abnormal bleeding. Anti-
depressant users are more likely to be hospitalized for abnormal
bleeding (Meijer et al., 2004) and lose more blood during elec-
tive surgery (van Haelst et al., 2010). A recent population based
case-control study in Denmark found that SSRI users are also at
modestly increased risk of upper gastrointestinal bleeding, but the
risk increases furtherwhenSSRIs are used in associationwith other
anti-thrombotic drugs, such as NSAIDs (Table 4; Dall et al., 2009).
CARDIAC EVENTS
Depression is associated with an increased risk of cardiovascular
disease, particularly myocardial infarction, coronary heart disease,
and stroke (Van der Kooy et al., 2007; Pozuelo et al., 2009). As
discussed above, these increased risks may be partly due to the
effects of serotonin on platelet activation. Researchers have there-
fore speculated that antidepressants that bind to the serotonin
transporter might be useful treatments for cardiac patients.
A recent study suggests that antidepressant usemayhelp protect
cardiac patients against cardiac related death while in the hospital
(Hata et al., 2011). However, several limitations of the study are
worth noting: speciﬁcally, the sample size was small, patients were
not randomized to the antidepressant treatment, and it was not
placebo-controlled. Indeed, the epidemiological literature on anti-
depressant effects on cardiac events is mixed. TCAs are generally
associated with an increase in cardiac events, due to anticholin-
ergic properties, NE reuptake blockade, and other effects (Cohen
et al., 1996; Tata et al., 2005). However, studies on SSRIs have pro-
duced mixed results, with some showing a protective effect (Sauer
et al., 2003; Monster et al., 2004; Schlienger et al., 2004), others
showing no effect (Cohen et al., 2000; Meier et al., 2001), and
still others showing an increased risk of cardiac events (Tata et al.,
2005). Moreover, controlled trials have not, at least thus far, shown
that SSRIs or psychotropic treatments have much effect on cardiac
events in cardiac patients (Pozuelo et al., 2009).
CEREBROVASCULAR EVENTS
In principle, the anticoagulant properties of SSRIs could reduce
occurrences of stroke, which could also increase survival in stroke
patients. One widely cited study has explored the mortality effects
of antidepressant treatment in the aftermath of stroke (Jorge
Table 4 | Risk of upper gastrointestinal bleeding as a function of
current use of SSRIs, aspirin, and other NSAIDs.
Medications used Adjusted odds ratio (95% CI)
SSRI alone 1.7 (1.01–2.8)
Aspirin alone 2.4 (1.72–3.3)
Other NSAIDs alone 4.3 (3.7–5.1)
SSRI and aspirin, no other NSAIDs 3.0 (0.96–9.2)
Aspirin and other NSAIDs, no SSRI 13 (8.7–20)
SSRI and other NSAIDs, no aspirin 8.0 (4.8–13)
SSRI, aspirin, and other NSAIDs 28 (7.6–103)
Adapted from Dall et al. (2009).
et al., 2003). One hundred and four stroke patients were ran-
domly assigned to 3months of antidepressant use (nortriptyline
or ﬂuoxetine) or placebo, and then followed up 9 years later.
Antidepressant use was associated with a signiﬁcantly higher 9-
year survival rate, which seems to contradict the epidemiological
ﬁndings discussed above. Unfortunately, the randomization was
unsuccessful. The patients in the placebo group were signiﬁcantly
more likely to have diabetes, and they tended to be older, more
obese,more likely to have atrial ﬁbrillation, andmore likely to have
chronic pulmonary obstruction, all of which are serious problems
that could have contributed to the highermortality rate. This study
has been criticized for failing to control for these differences and
other errors (Sonis, 2004;Ghaemi andThommi,2010). If the study
authors had re-analyzed the data controlling for these differences,
they could have silenced the critics, but the authors declined to do
so (Jorge et al., 2004).
Moreover, any beneﬁcial anticoagulant effects may be counter-
balanced by negative anticoagulant effects, so the overall effect
may be neutral. Indeed, large meta-analyses on the effects of other
anticoagulants in stroke patients ﬁnd that they have no net effect
on mortality (Paciaroni et al., 2007; Sandercock et al., 2008). Anti-
coagulants decrease the risk of recurrent ischemic strokes, but
this beneﬁt is offset by the increased risk of intracranial hemor-
rhages. Similarly, the beneﬁcial effects of anticoagulants in reduc-
ing the frequency of pulmonary emboli are counter-balanced by
the increased risk of extracranial hemorrhages (Sandercock et al.,
2008). Given the strength of this literature, it would be surpris-
ing if future research demonstrated an unambiguous positive net
effect of antidepressants on mortality in stroke patients.
It has also been argued that antidepressants could promote
recovery from stroke (Kramer, 2011). A recent randomized clin-
ical trial in France involved 118 patients with recent ischemic
stroke and given early treatment with ﬂuoxetine or placebo. The
ﬂuoxetine group showed greater motor recovery at a 90 day fol-
low up (Chollet et al., 2011). Given our discussion above, it is
unlikely that ﬂuoxetine promoted recovery due to a direct promo-
tion of neurogenesis. However, the clearance of damaged neurons
through apoptosis, the dematuration of adult neurons (which
might increase plasticity), and compensatory neurogenesis could
have all contributed to greater recovery. Another way in which
antidepressants could contribute to motor recovery after stroke is
by enhancing extracellular serotonin levels, since serotonin plays a
role in repetitive and grossmotor activity (Jacobs and Fornal, 1995,
1999). In any event, while promising, the effects of antidepressants
on motor recovery after stroke must be conﬁrmed.
REPRODUCTIVE FUNCTION
Serotonin is an important regulator of various aspects of repro-
duction (Azmitia, 2001). While depression is itself associated with
impaired sexual behavior,most antidepressants increase the degree
of impaired sexual functioning in men and women, including var-
ious aspects of desire, arousal, and orgasm (Serretti and Chiesa,
2009). TCAs and at least some SSRIs have adverse effects on sperm
motility, volume, and morphology (Hendrick et al., 2000; Tanrikut
et al., 2010). There are also case reports that antidepressants may
impair the affective dimensions of romantic love and attachment
(Fisher and Thomson, 2006).
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DEVELOPMENT
Serotonin plays important role in development (Azmitia, 2001), so
antidepressants could affect developmental processes. Depression
is common among pregnant and lactating mothers, and antide-
pressants are frequently prescribed (Moret et al., 2009; Ellfolk and
Malm, 2010). SSRIs pass through the placental barrier and mater-
nal milk, so antidepressants have the opportunity to affect the
development of the fetus and the neonate (Moret et al., 2009;
Ellfolk and Malm, 2010). When administered during pregnancy,
SSRIs may increase the risk of a preterm delivery and low birth
weight, although the results are mixed and inconclusive (Ellfolk
and Malm, 2010). Some SSRIs – particularly paroxetine – also
appear to be mild fetal teratogens (Bar-Oz et al., 2007; Cole et al.,
2007). In one meta-analysis, ﬁrst-term exposure to paroxetine
was associated with an adjusted odds ratio of 1.89 for congenital
defects (Cole et al., 2007). SSRI exposure during the third trimester
has been associated with medication withdrawal symptoms in the
newborn, including abnormal crying, irritability, and convulsions
(Moret et al., 2009; Ellfolk and Malm, 2010). Third trimester SSRI
exposure has also been associated with an increased risk of persis-
tent pulmonary hypertension in the newborn, which is a serious
condition with a mortality rate of about 10% (Ellfolk and Malm,
2010).
Researchers are continuing to investigate the long-term devel-
opmental effects of prenatal and neonatal exposure to SSRIs (Ell-
folk and Malm, 2010; Homberg et al., 2010). Recently, a study
found that fetal exposure to SSRIs, particularly during the ﬁrst
trimester, was associated with an increased risk of developing
autism spectrum disorders (Croen et al., 2011).
ELECTROLYTE HOMEOSTASIS
Serotonin is important in regulating water balance and electrolyte
homeostasis (Johnson and Thunhorst, 1997; Elgot et al., 2009;
Fonseca et al., 2009). The body normally keeps serum concentra-
tions of sodium within 135–145mEq/L, and hyponatremia occurs
when levels fall below 130mEq/L (Moret et al., 2009). Between
120 and 130mEq/L, hyponatremia can cause nausea, headache,
malaise and lethargy, muscle cramps, and disorientation. Lower
levels are associated with seizures, coma, respiratory arrest, and
death. Although the mechanism is unclear, SSRI use is associated
with an increased risk of hyponatremia in the elderly, with studies
showing an increased risk ranging from 0.5 to 32% (Jacob and
Spinler, 2006). A large epidemiological study in the UK found that
the risk of hyponatremia increased by 50% or more for several
commonly prescribed antidepressants – citalopram, escitalopram,
ﬂuoxetine, and venlafaxine (Coupland et al., 2011). The harmful
effects of hyponatremia may be exacerbated in patients who take
diuretics and other medications (Moret et al., 2009).
SUICIDAL BEHAVIOR
Depression is a risk factor for suicidal ideation and behavior,which
suggests that antidepressants might reduce these risks. However,
there is well-known controversy over whether antidepressant use
reduces or increases suicidal behavior (Baldessarini et al., 2007;
Reeves and Ladner, 2010). The largest, most recent meta-analyses
of randomized, placebo-controlled trials generally ﬁnd a positive
association between antidepressant use and suicidal behavior. In
one meta-analysis involving 702 trials and over 87,000 patients,
SSRI use was associated with an increased risk of suicide attempts
(Fergusson et al., 2005). In another meta-analysis of 342 random-
ized, double-blind, placebo-controlled trials submitted to the FDA
involving over 99,000 patients, antidepressant use was associated
with an increased risk of suicidal behavior in children, adolescents,
and young adults (Stone et al., 2009). But it had no overall effect in
adults aged 25–65, and it reduced the risk in the elderly. The rea-
son for the age effect is unknown and worth further investigation.
On the other hand, in a recent large epidemiological study in
the UK that controlled for many important covariates, includ-
ing depressive symptoms, patients over 65 years old who were not
taking any antidepressant had a 0.25% chance of harming them-
selves or making a suicide attempt over a 1 year period (Coupland
et al., 2011). However, the risk was higher for antidepressant use:
0.43% (TCAs), 0.55% (SSRIs), 1.30% (mirtazapine or venlafax-
ine). In short, the empirical literature is complex and it is not
possible to make any strong conclusions based on it, except that
antidepressant-induced suicide is rare (Baldessarini et al., 2007;
Reeves and Ladner, 2010). In any event, uncertainty about the
effects of antidepressants on suicidal behavior is germane to the
costs and beneﬁts of antidepressants.
OTHER SIDE EFFECTS
Reviews of other side effects are readily available (Brambilla et al.,
2005; Stahl, 2008; Zimmerman et al., 2010), so we do not address
them here. We merely note that 50–60% of antidepressant users
report experiencing gastrointestinal, sexual, and other signiﬁcant
side effects (Brambilla et al., 2005; Serretti and Chiesa, 2009;
Zimmerman et al., 2010), and that these side effects are unpleas-
ant enough that they are one of the most common reasons for
discontinuing them (Demyttenaere et al., 2001; Bull et al., 2002).
DO ANTIDEPRESSANTS DO MORE HARM THAN GOOD?
It is a principle of evolutionary medicine that the disruption of
evolved adaptations will degrade biological functioning. Antide-
pressants disrupt the functioning of the homeostatic mechanisms
that regulate serotonin throughout the body, and our review shows
that antidepressants have adverse effects on every major system
regulated by serotonin.
Antidepressants increase the brain’s susceptibility to future
episodes of depression (Andrews et al., 2011). They cause neuronal
damage (Kalia et al., 2000), apoptosis (Post et al., 2000;Bartholoma
et al., 2002; Sairanen et al., 2005), and dematuration (Kobayashi
et al., 2010). The evidence that antidepressants directly promote
neurogenesis is equivocal. It is quite possible that any neurogene-
sis that does take place is a compensatory response of the brain to
antidepressant-induced apoptosis. Antidepressants can also cause
problems in early development (Moret et al., 2009; Ellfolk and
Malm, 2010), and they have adverse effects on sexual and roman-
tic life (Fisher and Thomson, 2006; Serretti and Chiesa, 2009),
and an increased risk of hyponatremia (Jacob and Spinler, 2006),
bleeding (Meijer et al., 2004; Dall et al., 2009), and stroke (Smoller
et al., 2009; Triﬁro et al., 2010).
The primary beneﬁt of antidepressants is thought to be
the reduction of depressive symptoms, a view that presupposes
depression is the result of brain malfunction. An alternate view
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is that current diagnostic criteria do not accurately distinguish
between true instances of disorder and normal, evolved emo-
tional responses to stressors (Wakeﬁeld, 1992, 1999; Watson
and Andrews, 2002; Hagen, 2003; Horwitz and Wakeﬁeld, 2007;
Andrews and Thomson Jr., 2009; Andrews et al., 2011). This latter
view suggests that the pharmacological disruption of depressive
symptoms could negatively affect the ability to cope with or man-
age stressors. In any event, we reviewed several ﬁndings indicating
that the depressed brain pushes back against the symptom reduc-
ing effects of antidepressant medications (in patients meeting
diagnostic criteria for MDD) in ways indicating that depressive
symptoms are under homeostatic control. Thus, even by the debat-
able metric of symptom reduction, antidepressants are of limited
beneﬁt.
The limited symptom reducing effects of antidepressants, and
the largenumber of adverse health effects, suggests that antidepres-
sants could generally do more harm than good – though they may
be helpful for certain populations (e.g., those with brain cancers
or recovering from stroke). However, it is undoubtedly true that
the list of beneﬁcial and harmful effects of antidepressants that we
have listed in this review is incomplete. So, while we had difﬁculty
ﬁnding strong evidence of beneﬁcial effects, it is possible that anti-
depressants have a signiﬁcant beneﬁcial effect not yet identiﬁed.
Moreover, since the beneﬁts and costs are in different currencies,
it is difﬁcult to directly compare them. Finally, the effects differ in
their frequency and their effect size, and some of them are rare. In
some instances, we simply do not yet have information on effect
size or frequency (e.g., antidepressant triggered apoptosis). Each
of these issues could make it more difﬁcult to conclude what the
overall effect of antidepressants is.
These problems can largely be circumvented by examining
the effects of antidepressants on mortality. Mortality data nat-
urally synthesizes the multiple effects of a drug on biological
functioning, including those not considered or identiﬁed. If the
beneﬁcial effects of antidepressants in reducing anyharmful symp-
toms outweigh the detrimental effects in disrupting homeostatic
mechanisms, then they should increase survival. Conversely, if the
harmful effects of antidepressants outweigh the beneﬁcial effects,
then they should decrease survival.
Depression itself is associated with an increased risk of death,
primarily through its effects on cardiovascular disease (Van der
Kooy et al., 2007; Pozuelo et al., 2009). But does antidepressant use
increase or decrease the risk of death? Three recent, large, prospec-
tive epidemiological studies have found that, even after controlling
for depressive symptoms, antidepressant use is associated with an
increased risk of death in the elderly (Smoller et al., 2009; Almeida
et al., 2010; Coupland et al., 2011).
Themost recent study involved patients in theUnitedKingdom
over 65 years old (average age= 75) who had received a diagno-
sis of depression between 1996 and 2007 (Coupland et al., 2011).
The 1-year risk of death after controlling for a large number of
covariates (including the severity of depressive symptoms) was as
follows: 7.04% (no antidepressant use), 8.12% (TCAs), 10.61%
(SSRIs), and 11.43% (other antidepressants). Put another way,
out of 1000 elderly people taking antidepressants, the number of
deaths per year caused by antidepressants was estimated to be 10.8
(for TCAs), 35.7 (for SSRIs), and 43.9 (for other antidepressants).
Another study estimated that antidepressants caused the deaths
of roughly 5 in 1000 elderly women per year, with no differences
in the class of antidepressant (Smoller et al., 2009). The lower
estimate in this study could be due to the fact that the women
were somewhat younger (age range= 50–79) and perhaps more
resilient to the harmful effects of antidepressants.
In comparison, rofecoxib (Vioxx) was pulled off the market
amidst evidence that it caused about 7.2 cardiovascular events per
1000 patient-years and a lower risk of death (Bresalier et al., 2005).
An important limitation is that theVioxx studieswere randomized,
placebo-controlled experiments, while the antidepressant studies
were not. But the antidepressant-mortality surveys nevertheless
suggest that antidepressants are increasing the risk of death, a point
that can only be deﬁnitively disproved by conducting controlled
experiments on the mortality effects of antidepressants.
Another important limitation of the antidepressant-mortality
studies is the fact that they deal exclusively with the elderly. It
is possible that young adults who take antidepressants are more
resilient to their harmful effects andwill experience amuch smaller
risk of death than the elderly, although this should not simply be
assumed. Moreover, many people take antidepressants for years
throughout their adult life, and it is unclear what the cumulative
impact is over years of use. The cumulative effects of antidepres-
sants on the integrity of the brain and peripheral processes could
shorten the lifespan considerably. Current research is unable to
rule out this possibility.
CONCLUSION
We have reviewed a great deal of evidence of the effects of antide-
pressants on serotonergic processes throughout the body. Some of
the effects are widely known, but they have been largely ignored
in debates about the utility of antidepressants. Indeed, it is widely
believed that antidepressant medications are both safe and effec-
tive; however, this belief was formed in the absence of adequate
scientiﬁc veriﬁcation. The weight of current evidence suggests
that, in general, antidepressants are neither safe nor effective; they
appear to do more harm than good.
Further research on their effects is clearly needed. We note a
few areas of particular importance. First, after antidepressant dis-
continuation some people report depressive symptoms that are
more severe than the initial symptoms that prompted antidepres-
sant treatment. This should be formally tested, and if conﬁrmed
it would provide further support for the homeostatic rebound
argument we presented above. Second, more research should be
conducted on how best to interpret the BrdU signal in the con-
text of antidepressant use. Does it reﬂect apoptosis, neurogene-
sis, or both? Particularly helpful would be studies that examine
the temporal relationship between the BrdU signal and inde-
pendent measures of apoptosis and neurogenesis. Third, more
studies should examine the morphological changes in neurons
that take place with repeated administration of serotonergic anti-
depressants (Kalia et al., 2000). Fourth, greater research should
be devoted to exploring the possibility that the effects of pro-
longed antidepressant use on neuronal integrity may cause cog-
nitive decline and dementia (Jackson, 2008; Goveas et al., 2011).
Finally, greater research should be devoted to the effects of anti-
depressants on longevity. The quickest experiments could be done
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on rodents. That such studies were not done decades ago, before
antidepressants were approved for widespread use, is troublesome.
Such researchwill give us a better picture of the effects of antide-
pressants onoverall functioning.Nevertheless, froma legal, ethical,
and public health perspective, it now seems prudent, on the basis
of existing evidence, for individual practitioners and professional
medical organizations to revise informed consent guidelines and
reconsider the status of antidepressants in standards of care for
many diagnoses and as the immediate front line treatment for
depression. Some patients may be more likely to beneﬁt from
antidepressants and less likely to suffer adverse effects, but identi-
fying them will require further research and greater understanding
of the etiology of depression.
Patients should be informed that current research suggests that
unless they have very severe depression, the symptom reducing
effects of antidepressants are modest and are not considered clin-
ically signiﬁcant. Unless there are rapid-onset adverse side effects,
antidepressant therapy usually lasts for months. Patients should be
advised that prolongedusemight causemild cognitive impairment
and interfere with tasks that require highly focused concentra-
tion, such as driving, which may increase the risk of accidents.
Patients should also be advised that antidepressants might trigger
even more severe depressive episodes when they are discontinued.
All patients should be advised of the possible bleeding risks, and
physicians should exercise particular caution in prescribing these
drugs in conjunction with other diuretic or anti-thrombotic med-
ications. The evidence of harm is strongest in the elderly, who
should be advised of the risks of falling, hyponatremia, bleeding,
stroke, and death.
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